Vera van der Noord
- Name
- Dr. V.E. van der Noord
- ORCID iD
- 0000-0002-9894-3239
- Noord V.E. van der, McLaughlin R.P., Karuntu J.S., He J., Timmermans A.M., Basnet S.K.C., Long Y., Diab S.A.H., Tadesse S., Proost N., Gerwen B., Siteur B., Ven M. van de, Pont C., Le Dévédec S.E., Martens J.W.M., Wang S., Zhang Y. & Water B. van de (2026), Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR inhibition, Cellular Oncology 49(1): 20.
- Bergonzini C., Gregori A., Hagens T.M.S., Noord V.E. van der, Water B. van de, Zweemer A.J.M., Coban B., Capula M., Mantini G., Botto A., Finamore F., Garajova I., McDonnell L.A., Schmidt T., Giovannetti E. & Danen E.H.J. (2024), ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells, Journal of Experimental & Clinical Cancer Research 43: 4.
- Noord V.E. van der (25 April 2024), Disrupting the transcriptional machinery to combat triple-negative breast cancer (Dissertatie. Leiden Academic Centre for Drug Research (LACDR), Faculty of Science, Leiden University). Supervisor(s) and Co-supervisor(s): Water B. van de, Le Dévédec S.E.
- Abyar S., Huang L., Husiev Y., Bretin L.R., Chau B., Vadde R., Wildeman J.H., Belfor K., Wijyay L.S., Noord V.E. van der, Harms A.C., Siegler M.A., Le Dévédec S.E. & Bonnet S.A. (2024), Oxygen-dependent interactions between the ruthenium cage and the photoreleased inhibitor in NAMPT-targeted photoactivated chemotherapy, Journal of Medicinal Chemistry 67(13): 11086–11102.
- Noord V.E. van der, Stel W. van der, Louwerens G., Verhoeven D., Kuiken H.J., Lieftink C., Grandits M., Ecker G.F., Beijersbergen R.L., Bouwman R.J.P., Le Dévédec S.E. & Water B. van de (2023), Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors, Breast Cancer Research 25(1): 51.
- Liu Q., Liu N.S., Noord V.E. van der, Stel W. van der, Water B. van de, Danen E.H.J. & Le Dévédec S.E. (2023), Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia, Breast Cancer Research and Treatment 198: 583-596.
- Liu Q., Stel W. van der, Noord V.E. van der, Leegwater H., Coban B., Elbertse K., Pruijs J.T.M., Béquignon O.J.M., Westen G.J.P. van, Dévédec S.E. le & Danen E.H.J. (2022), Hypoxia triggers TAZ phosphorylation in basal a triple negative breast cancer cells, International Journal of Molecular Sciences 23(17): 10119.
- Noord V.E. van der, Water B. van de & Le Dévédec S.E. (2022), Targeting the heterogeneous genomic landscape in triple-negative breast cancer through inhibitors of the transcriptional machinery, Cancers 14(18): 4353.
- He J., McLaughlin R.P., Noord V.E. van der, Foekens J.A., Martens J.W.M., Westen G.J.P. van, Zhang Y. & Water B. van de (2019), Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer, Breast Cancer Research and Treatment 178(2): 263-274.
- McLaughlin R.P., He J., Noord V.E. van der, Redel J., Foekens J.A., Martens J.W.M., Smid M., Zhang Y. & Water B. van de (2019), A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy, Breast Cancer Research 21: 77.
- Noord V.E. van der, McLaughlin R.P., Smid M., Foekens J.A., Martens J.W.M., Zhang Y. & Water B. van de (2019), An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer, Scientific Reports 9(1): 13308.
- Koenders S.T.A., Wijaya L.S., Erkelens M.N., Bakker A.T., Noord V.E. van der, Rooden E.J. van, Burggraaff L., Putter P.C., Botter E., Wals K., Elst H. van den, Dulk H. den, Florea B.I., Water B. van de, Westen G.J.P. van, Mebius R.E., Overkleeft H.S., Le Dévédec S.E. & Stelt M. van der (2019), Development of a Retinal-Based Probe for the Profiling of Retinaldehyde Dehydrogenases in Cancer Cells, ACS Central Science 5(12): 1965-1974.